Background & Aims Liquid biopsies, or blood samples, can be analyzed to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles, which might identify …
Cancer is the second leading cause of death globally and is projected to overtake infectious disease as the leading cause of mortality in Africa within the next two decades. Cancer is a …
DM Marzese, H Hirose, DSB Hoon - Expert review of molecular …, 2013 - Taylor & Francis
Qualitative and quantitative analysis of circulating cell-free DNA (cfDNA) is an emerging non- invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis …
F Pelizzaro, R Cardin, B Penzo, E Pinto, A Vitale… - Cancers, 2021 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is one of the mostly lethal cancers, with a prognosis which is still very poor. Novel reliable biomarkers, useful in early diagnosis and …
B Kucukcakan, Z Hayrulai-Musliu - Open access Macedonian …, 2015 - ncbi.nlm.nih.gov
Aflatoxins (AFT) are poisonous substances which are classified in Group 1 carcinogenic agents to humans by International Agency for Research on Cancer (IARC). AFT can occur …
H Wang, P Liao, SX Zeng, H Lu - Journal of molecular cell …, 2019 - academic.oup.com
Abstract Gain-of-function (GOF), the most malicious oncogenic activity of a cancer-promoting protein, is well illustrated to three hotspot p53 mutations at R248, R175, and R273 with …
YH Su, AK Kim, S Jain - Translational Research, 2018 - Elsevier
Hepatocellular carcinoma (HCC) is the world's second leading cause of cancer death; 82.4% of patients die within 5 years. This grim prognosis is the consequence of a lack of …
A Marchio, M Amougou Atsama, A Béré… - Clinical and …, 2018 - Springer
Hepatocellular carcinoma (HCC) is still a major killing malignancy in sub-Saharan Africa. Lifelong intoxication with aflatoxin B1 is considered as one of the primary causes of this …
SY Lin, V Dhillon, S Jain, TT Chang, CT Hu… - The Journal of Molecular …, 2011 - Elsevier
Hepatocellular carcinoma (HCC) has a 5-year survival rate of< 10% because it is difficult to diagnose early. Mutations in the TP53 gene are associated with approximately 50% of …